Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to $97.5 million.

  • Oncology Institute's Shares Outstanding (Diluted Average) rose 2906.33% to $97.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.5 million, marking a year-over-year increase of 2906.33%. This contributed to the annual value of $75.0 million for FY2024, which is 175.6% up from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's Shares Outstanding (Diluted Average) is $97.5 million, which was up 2906.33% from $93.2 million recorded in Q2 2025.
  • Over the past 5 years, Oncology Institute's Shares Outstanding (Diluted Average) peaked at $97.5 million during Q3 2025, and registered a low of $62.9 million during Q1 2021.
  • Over the past 5 years, Oncology Institute's median Shares Outstanding (Diluted Average) value was $74.7 million (recorded in 2024), while the average stood at $75.6 million.
  • As far as peak fluctuations go, Oncology Institute's Shares Outstanding (Diluted Average) soared by 18705.14% in 2021, and later crashed by 850.68% in 2023.
  • Over the past 5 years, Oncology Institute's Shares Outstanding (Diluted Average) (Quarter) stood at $66.2 million in 2021, then grew by 21.7% to $80.6 million in 2022, then decreased by 8.51% to $73.7 million in 2023, then increased by 1.76% to $75.0 million in 2024, then increased by 29.89% to $97.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $97.5 million in Q3 2025, compared to $93.2 million in Q2 2025 and $77.1 million in Q1 2025.